Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;21 Suppl 2(Suppl 2):90-8.
doi: 10.1002/pds.3250.

Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment

Affiliations

Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment

Jennifer M Polinski et al. Pharmacoepidemiol Drug Saf. 2012 May.

Abstract

Purpose: Under Medicare Part D, patient characteristics influence plan choice, which in turn influences Part D coverage gap entry. We compared predefined propensity score (PS) and high-dimensional propensity score (hdPS) approaches to address such "confounding by health system use" in assessing whether coverage gap entry is associated with cardiovascular events or death.

Methods: We followed 243,079 Medicare patients aged 65+ years with linked prescription, medical, and plan-specific data in 2005-2007. Patients reached the coverage gap and were followed until an event or year's end. Exposed patients were responsible for drug costs in the gap; unexposed patients (patients with non-Part D drug insurance and Part D patients receiving a low-income subsidy) received financial assistance. Exposed patients were 1:1 PS-matched or hdPS-matched to unexposed patients. The PS model included 52 predefined covariates; the hdPS model added 400 empirically identified covariates. Hazard ratios for death and any of five cardiovascular outcomes were compared. In sensitivity analyses, we explored residual confounding using only low-income subsidy patients in the unexposed group.

Results: In unadjusted analyses, exposed patients had no greater hazard of death (HR = 1.00; 95%CI, 0.84-1.20) or other outcomes. PS-matched (HR = 1.29; 0.99-1.66) and hdPS-matched (HR = 1.11; 0.86-1.42) analyses showed elevated but non-significant hazards of death. In sensitivity analyses, the PS analysis showed a protective effect (HR = 0.78; 0.61-0.98), whereas the hdPS analysis (HR = 1.06; 0.82-1.37) confirmed the main hdPS findings.

Conclusion: Although the PS-matched analysis suggested elevated but non-significant hazards of death among patients with no financial assistance during the gap, the hdPS analysis produced lower estimates that were stable across sensitivity analyses.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr. Polinski is a consultant to Buccaneer Computer Systems and Service, Inc., a contractor for the Centers for Medicare and Medicaid Services. Within the past 5 years, Dr. Polinski’s spouse was employed as an engineer by DePuy Orthopaedics, a subsidiary of Johnson & Johnson, and had Johnson & Johnson stock totaling < $3100 in value. Dr. Schneeweiss was a paid member of the Scientific Advisory Board of HealthCore and is a consultant to World Health Information Science Consultants, LLC. Dr. Schneeweiss is Principal Investigator of the Brigham and Women’s Hospital DEcIDE Center on Comparative Effectiveness Research funded by AHRQ and the DEcIDE Methods Center. Dr. Schneeweiss received funding through investigator-initiated grants awarded to his employer, Brigham and Women’s Hospital, from Pfizer, Novartis, and Boehringer-Ingelheim. Dr. Glynn has worked on grants to the Brigham & Women’s Hospital, his employer, from Astra Zeneca and Novartis related to the design, statistical monitoring, and analysis of clinical trials in the setting of cardiovascular drugs. Dr. Glynn has worked on grants to the Brigham & Women’s Hospital, his employer, from Astra Zeneca and Novartis related to the design, statistical monitoring, and analysis of clinical trials in the setting of cardiovascular drugs. Dr. Glynn also signed a consulting agreement to give a one-time Grand Rounds talk on comparative effectiveness research methods at Merck. Dr. Rassen is a consultant to Phase Forward. Opinions expressed here are only those of the authors and not necessarily those of the agencies.

Similar articles

Cited by

References

    1. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–37. - PubMed
    1. Polinski JM, Kilabuk E, Schneeweiss S, Brennan TA, Shrank WH. Changes in Drug Use and Out-of-Pocket Costs Associated with Medicare Part D Implementation: A Systematic Review. J Am Geriatr Soc. 2010;58:1764–79. - PMC - PubMed
    1. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59:437–47. - PMC - PubMed
    1. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol. 2003;92:1447–51. - PubMed
    1. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149–56. - PMC - PubMed

Publication types

MeSH terms

Substances